Englander Institute for Precision Medicine

Publications

Found 690 results
Author Title Type [ Year(Asc)]
2023
Orme JJ, Taza F, De Sarkar N, Tewari AK, Naqvi SArsalan, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R et al..  2023.  Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.. Eur Urol Oncol.
Huang SH, Sartorello G, Shen P-T, Xu C, Elemento O, Shvets G.  2023.  Correction: Metasurface-enhanced infrared spectroscopy in multiwell format for real-time assaying of live cells.. Lab Chip. 23(17):3893.
Popic V, Rohlicek C, Cunial F, Hajirasouliha I, Meleshko D, Garimella K, Maheshwari A.  2023.  Cue: a deep-learning framework for structural variant discovery and genotyping.. Nat Methods. 20(4):559-568.
Liu W, Newhall KP, Khani F, Barlow LM, Nguyen D, Gu L, Eng K, Bhinder B, Uppal M, Récapet C et al..  2023.  The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.. Cancer Res. 83(4):506-520.
Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, E Crawford D, Shore N, Kopyltsov E, Kalebasty ARezazadeh, Bögemann M et al..  2023.  Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.. J Clin Oncol. 41(20):3595-3607.
Assaad MAl, Shin N, Sigouros M, Manohar J, Antysheva Z, Kotlov N, Kiriy D, Nikitina A, Kleimenov M, Tsareva A et al..  2023.  Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis.. Front Oncol. 13:1274163.
Yao P, Witte D, German A, Periyakoil P, Kim YEun, Gimonet H, Sulica L, Born H, Elemento O, Barnes J et al..  2023.  A deep learning pipeline for automated classification of vocal fold polyps in flexible laryngoscopy.. Eur Arch Otorhinolaryngol.
Darabedian N, Ji W, Fan M, Lin S, Seo H-S, Vinogradova EV, Yaron TM, Mills EL, Xiao H, Senkane K et al..  2023.  Depletion of creatine phosphagen energetics with a covalent creatine kinase inhibitor.. Nat Chem Biol. 19(7):815-824.
Yusupova M, Zhou D, You J, Gonzalez-Guzman J, Ghanta MB, Pu H, Abdel-Malek Z, Chen Q, Gross SS, D'Orazio J et al..  2023.  Distinct cAMP signaling microdomains differentially regulate melanosomal pH and pigmentation.. J Invest Dermatol.
Klapp V, Álvarez-Abril B, Leuzzi G, Kroemer G, Ciccia A, Galluzzi L.  2023.  The DNA Damage Response and Inflammation in Cancer.. Cancer Discov. 13(7):1521-1545.
Mirjolet C, Baude J, Galluzzi L.  2023.  Dual impact of radiation therapy on tumor-targeting immune responses.. Int Rev Cell Mol Biol. 378:xiii-xxiv.
Merdler-Rabinowicz R, Gorelik D, Park J, Meydan C, Foox J, Karmon M, Roth HS, Cohen-Fultheim R, Shohat-Ophir G, Eisenberg E et al..  2023.  Elevated A-to-I RNA editing in COVID-19 infected individuals.. NAR Genom Bioinform. 5(4):lqad092.
Galluzzi L, Aryankalayil MJ, C Coleman N, Formenti SC.  2023.  Emerging evidence for adapting radiotherapy to immunotherapy.. Nat Rev Clin Oncol.
González-Muñoz T, Di Giannatale A, García-Silva S, Santos V, Sánchez-Redondo S, Savini C, Graña-Castro O, Blanco-Aparicio C, Fischer S, De Wever O et al..  2023.  Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis.. Clin Cancer Res. 29(18):3744-3758.
Cappelli LVincenzo, Fiore D, Phillip JM, Yoffe L, Di Giacomo F, Chiu W, Hu Y, Kayembe C, Ginsberg M, Consolino L et al..  2023.  Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.. Blood. 141(5):503-518.
Galassi C, Galluzzi L.  2023.  Epigenetic escape of immunosurveillance by malignant cell precursors.. EMBO J. 42(10):e114050.
Cheong J-G, Ravishankar A, Sharma S, Parkhurst CN, Grassmann SA, Wingert CK, Laurent P, Ma S, Paddock L, Miranda IC et al..  2023.  Epigenetic memory of coronavirus infection in innate immune cells and their progenitors.. Cell. 186(18):3882-3902.e24.
Lin T-Y, Ramsamooj S, Perrier T, Liberatore K, Lantier L, Vasan N, Karukurichi K, Hwang S-K, Kesicki EA, Kastenhuber ER et al..  2023.  Epinephrine inhibits PI3Kα via the Hippo kinases.. Cell Rep. 42(12):113535.
Li D, Zhan Y, Wang N, Tang F, Lee CJ, Bayshtok G, Moore AR, Wong EWP, Pachai MR, Xie Y et al..  2023.  ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer.. Sci Adv. 9(14):eadc9446.
Khani F, Hooper WF, Wang X, Chu TR, Shah M, Winterkorn L, Sigouros M, Conteduca V, Pisapia D, Wobker S et al..  2023.  Evolution of structural rearrangements in prostate cancer intracranial metastases.. NPJ Precis Oncol. 7(1):91.
Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN et al..  2023.  External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.. J Clin Oncol. 41(15):2736-2746.
Chen HJoyce, Gardner EE, Shah Y, Zhang K, Thakur A, Zhang C, Elemento O, Varmus H.  2023.  FORMATION OF MALIGNANT, METASTATIC SMALL CELL LUNG CANCERS THROUGH OVERPRODUCTION OF cMYC PROTEIN IN TP53 AND RB1 DEPLETED PULMONARY NEUROENDOCRINE CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS.. bioRxiv.
Sternberg CN, Petrylak DP, Bellmunt J, Nishiyama H, Necchi A, Gurney H, Lee J-L, van der Heijden MS, Rosenbaum E, Penel N et al..  2023.  FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on / mRNA Expression.. J Clin Oncol. 41(3):629-639.
Ladewig MS, Jacobsen JOB, Wagner AH, Danis D, Kassaby BEl, Gargano M, Groza T, Baudis M, Steinhaus R, Seelow D et al..  2023.  GA4GH Phenopackets: A Practical Introduction.. Adv Genet (Hoboken). 4(1):2200016.
Weinstock JS, Laurie CA, Broome JG, Taylor KD, Guo X, Shuldiner AR, O'Connell JR, Lewis JP, Boerwinkle E, Barnes KC et al..  2023.  The genetic determinants of recurrent somatic mutations in 43,693 blood genomes.. Sci Adv. 9(17):eabm4945.